<DOC>
	<DOCNO>NCT00030602</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . PURPOSE : Phase II trial study effectiveness vaccine therapy treat patient recurrent prostate cancer .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Recurrent Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine effect PSA-3 peptide vaccine emulsify Montanide ISA-51 PSA level patient recurrent prostate cancer . II . Determine toxicity regimen patient . III . Determine whether T lymphocyte immune response PSA-3 HLA-A2 antigen-presenting cell endogenously produce PSA increase patient treated regimen . IV . Determine duration PSA and/or immune responses patient treated regimen . V. Correlate immune PSA responses patient treated regimen . VI . Determine efficacy second ( boost ) vaccination regimen patient PSA immune response . OUTLINE : This multicenter study . Patients receive PSA-3 peptide vaccine emulsify Montanide ISA-51 subcutaneously 2 site day 1 , 8 , 15 , 22 absence unacceptable toxicity . Patients show immune prostate specific antigen ( PSA ) response follow disease progression , define diminution disappearance immune response 2 consecutive increase PSA nadir . Patients eligible second series injection time progression . PROJECTED ACCRUAL : A total 14-44 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven adenocarcinoma prostate Previously treat radical prostatectomy least 3 month ago HLAA2 positive PSA great 0.5 ng/mL rise At least 0.3 ng/mL great postprostatectomy nadir Confirmed least 2 additional PSA level least 2 week apart No bone metastases bone scan within past 3 month No clinical evidence local disease recurrence ( palpable mass induration prostatic fossa ) PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 01 OR Karnofsky 70100 % Life expectancy : More 1 year Hematopoietic : WBC least 3,000/mm3 Hepatic : Bilirubin normal AST ALT great 2.5 time upper limit normal Renal : Creatinine normal Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other : Fertile patient must use effective contraception HIV negative No clinical immune dysfunction illness ( e.g. , rheumatoid arthritis ) No ongoing active infection No concurrent uncontrolled illness would preclude study No concurrent psychiatric illness social situation would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Neoadjuvant hormonal therapy prior prostatectomy allow No concurrent hormonal therapy recurrent prostate cancer Radiotherapy : No prior radiotherapy prostate No prior radiotherapy pelvis Surgery : See Disease Characteristics Other : No concurrent investigational agent No concurrent commercial agent intend treat malignancy No concurrent immunosuppressive therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>